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Abstract 
Methamphetamine is a highly addictive psychostimulant drug with serious health consequences 
that include long-term neurotoxic effects. While the neurotoxic mechanisms are still not fully 
understood, monoamine release, production of reactive oxygen species and excitotoxicity are 
believed to be involved. There is currently no effective treatment to prevent these effects. Using 
metabolomic analysis to explore the effect of methamphetamine on neuronal cells with dose and 
time may help to elucidate the biochemical pathways affected, and provide an insight into 
methamphetamine neurotoxicity. 
A B50 neuroblastoma cell culture model was used in these experiments. Cell viability was assessed 
by lactate dehydrogenase assay and Trypan blue exclusion testing after 48 hours exposure to 1 mM 
methamphetamine. A dose curve was conducted exposing cells to a range of methamphetamine 
doses (100 nM, 1 µM, 10 µM, 100 µM and 1 mM) over 48 hours. A time course examined the 6-, 
24- and 48-hour time points after B50 exposure to 1 mM methamphetamine. A gas 
chromatography-mass spectrometry metabolomic method was used to analyse the treated cells and 
cell media of the dose curve and time course. The metabolites found to contribute most to the 
variance between the samples were chosen for further study. 
Methamphetamine caused observable damage to B50 cells and cell viability which was found to be 
dose-dependent by Trypan blue testing, however, LDH results were inconclusive. The metabolites 
found to change over dose and time during methamphetamine exposure included amino acids, 
carbohydrates and fatty acids. The dose curve showed a build-up of carbohydrates, a decrease in 
octadecenoate and alterations to many amino acids with increasing dose. The results from the time 
course found an increase in L-glutamate and related metabolites, an increase in antioxidant amino 
acids and a decrease in carbohydrates over time.  The changes suggest glutamate release, reactive 
oxygen species and disturbances to energy utilisation may be involved in the effect of 
methamphetamine upon neuronal cells. 
The study has confirmed that methamphetamine causes dose-dependent damage and death of 
neurons. Methamphetamine exposure resulted in quantifiable biochemical changes over dose and 
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time with the metabolite changes reflecting the known mechanisms of methamphetamine 
neurotoxicity. The result of this study furthers our understanding of neurochemical processes in 
response to methamphetamine and could potentially lead to the identification of therapeutic targets.  
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1. Introduction 
 
The amphetamine derivative, methamphetamine, also known as “meth”, “speed” and “crank” is a 
powerful psychoactive drug. Whilst nearly identical in structure, methamphetamine is more potent 
than amphetamine (Figure 1.0), with effective doses of 0.06 and 0.28 mg/kg respectively 
(Bondareva et al., 2002). This is thought to be due to the presence of an additional methyl group on 
the amine making the compound more stable and lipid soluble, aiding its transport across the blood 
brain barrier (Carvalho et al., 2012). Two isomeric forms of methamphetamine exist; (+) 
methamphetamine and (-) methamphetamine, with the former being dominant and five times more 
biologically active (Schep et al., 2010). Methamphetamine has stimulant, euphoric, anorectic and 
hallucinogenic properties. It is highly abused for its effects of increased concentration, reduced 
need for food and sleep and for feelings of well-being. In addition to these sought after effects, 
methamphetamine causes anxiety, psychosis, cognitive and motor impairments, stroke, cardiac 
irregularities and death (Cadet et al., 2007). 
 
 
Figure 1.0: Chemical structures of methamphetamine and other psychostimulants ephedrine, 
MDMA (methylenedioxymethamphetamine or ecstasy), amphetamine, pseudoephedrine and 
cocaine (adapted from Vearrier et al., 2012). 
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1.1 The methamphetamine problem 
While methamphetamine‟s beginnings were innocent, misuse of the drug has developed into a 
global problem. Since its synthesis in 1919 by Japanese chemist Akira Ogata, methamphetamine 
has had a range of uses. Similar to amphetamine, methamphetamine was first put to use for nasal 
decongestion and for the treatment of asthma (Vearrier et al., 2012). It was also used as a diet aid 
and to combat depression and alcoholism (Watanabe-Galloway et al., 2009). During World War II 
methamphetamine was favoured by the German and Japanese militaries for its stimulant properties, 
keeping soldiers awake and alert. However, adverse effects soon made themselves known with 
reports of increased blood pressure and heart rate, palpitations, convulsions, tremor and difficulty 
breathing. Restrictions were put in place, limiting the availability of methamphetamine to 
prescription only, eventually outlawing the drug completely. These measures were mostly 
ineffective for soon after these restrictions were put in place, the first clandestine laboratories 
appeared (Vearrier et al., 2012).  
 
There are two main methods for the production of methamphetamine: the phenyl-2-propanone 
(P2P) method, which uses P2P and methylamine as precursors and the ephedrine/pseudoephedrine 
reduction method (Figure 1.1). Clandestine labs mostly use the ephedrine/pseudoephedrine method 
as it is simple and is based on easily available household products such as acetone, lithium (lithium 
batteries), sodium hydroxide (lye), toluene (paint thinner) and ephedrine/pseudoephedrine (cold 
and allergy medication). This has resulted in the restricted sale of some of these goods (Weisheit, 
2008); however, its effectiveness in reducing production is questionable due to lack of 
comprehensive control (Schloenhardt, 2007). Substitution of new ingredients to replace those 
restricted has resulted in a reduction in purity with the median purity being between 1.9 and 49.9% 
in Australia (Australian Crime Commission, 2012). Some of these impurities and adulterants can 
result in adverse consequences or death. A report by the US Centres for Disease Control (1990) 
discovered eight cases of lead poisoning due to intravenous methamphetamine use where the drug 
samples tested contained up to 60% lead by weight. 
 
3 
 
 
Figure 1.1: The two major routes of methamphetamine synthesis; the ephedrine/pseudoephedrine 
reduction method (top) and the phenyl-2-propanone (P2P) method (bottom) (Mendelson et al., 
2006). 
 
 
As a result of its availability, low cost and long duration of action methamphetamine has a high 
potential for abuse. The United Nations Office on Drugs and Crime 2008 report estimated that 
there were 25 million methamphetamine users worldwide, exceeding the use of cocaine and heroin 
(Panenka et al., 2012). In Australia, estimates place the number of people over 14 years of age who 
have used methamphetamine in the last 12 months at 2.1 % (Australian Institute of Health and 
Welfare, 2011). Associated with a high risk of unemployment and financial trouble, psychological 
and health problems and violent and criminal behaviour, methamphetamine addiction places a 
great burden on society (Brecht et al., 2004). Amphetamine stimulants account for 15% of national 
illicit drug arrests second only to cannabis (Australian Crime Commission, 2012).  
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1.2 Effects of methamphetamine 
Methamphetamine users seek the drug‟s pleasurable effects such as euphoria, decreased appetite 
and increased alertness, concentration and libido. However, in seeking these effects, users are 
risking their lives as methamphetamine use has a dark side. The damaging effects of 
methamphetamine on the body are multiple and wide spread including cardiovascular, cognitive, 
developmental, dental caries and neurotoxic effects (Barr et al., 2006). 
1.2.1 Cardiovascular effects 
Methamphetamine is frequently associated with severe cardiovascular symptoms, the 
complications from which are often a cause of death in users. The cardiovascular effects of 
methamphetamine are due to the release of the catecholamine neurotransmitters adrenaline and 
noradrenaline. These compounds activate β-adrenergic receptors causing an increase in heart rate. 
The oxidative stress associated with methamphetamine abuse can also cause cardiotoxicity. 
Combined, these effects interfere with cardiac homeostasis and impair heart function. Immediate 
cardiovascular effects include increased heart rate, tachycardia and increased blood pressure, 
sometimes lasting several hours. Vascular effects include hypertension, stroke and haemorrhage. 
Methamphetamine abuse is also linked with an increased risk of myo-cardial infarction, ventricular 
hypertrophy, arrhythmias and cardiomyopathy. A study of cardiomyopathy patients found that 4 of 
10 patients under 45 years of age had a history of methamphetamine abuse. This suggests that 
young people who use methamphetamine are at higher risk of developing cardiomyopathy than 
non-users. (Carvalho et al., 2012). 
1.2.2 Cognitive effects 
While a single low dose of methamphetamine may improve attention and cognitive processing, 
chronic use leads to severe neuropsychological problems. Many processes are affected by 
methamphetamine use, with the most consistent being impairments in working memory, executive 
function and attention (Barr et al., 2006). Methamphetamine users may also experience problems 
with learning and decision making (Cadet et al., 2007). Specificity to these areas is thought to be 
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due to the rich dopaminergic innervation of pathways controlling cognitive processes which 
methamphetamine is known to target (Barr et al., 2006). 
One of the most serious cognitive effects associated with methamphetamine abuse is the 
development of drug-related psychosis. Very similar in nature to schizophrenia, this enduring 
effect results from high dose or continuous methamphetamine use (Levi et al., 2012). A Japanese 
survey of young people who regularly used methamphetamine found 80% had suffered from 
psychotic symptoms. This has raised concern as those who suffer repeated psychotic episodes are 
less responsive to treatment (Barr et al., 2006).  
1.2.3 Developmental effects 
Methamphetamine is increasingly becoming the drug of choice for drug-dependent women during 
pregnancy. In a study of drug use in pregnant women, only 35% decreased their methamphetamine 
use, while 10% increased and 55% made no change. These women were also less likely to seek 
prenatal advice (Della Grotta et al., 2010). Methamphetamine is able to quickly cross the placenta 
and distributes to the foetal organs where it causes changes such as increased heart weight and 
myocardial damage. Other problems include hypoxia, hyperglycemia and hypertension. At birth, 
these infants often show a decreased weight, length and head circumference (Schep et al., 2010). 
Children who have been exposed in utero perform poorly on attention and verbal memory tests. 
They also display changes in brain development, with smaller striatal and hippocampal volumes 
which may account for their cognitive problems (Chang et al., 2007). 
1.2.4 “Meth mouth” 
Methamphetamine has devastating effects on oral health. “Meth mouth” has become the term used 
to describe the decay and oral problems associated with methamphetamine abuse (Figure 1.21). 
Methamphetamine users often neglect their oral hygiene and frequently favour sugary drinks 
during times of drug use. Dehydration and stimulation of the sympathetic nervous system reduce 
the amount of saliva produced leading to development of dental caries. Also contributing to tooth 
decay are the acidic substances used in the production of methamphetamine. Users of 
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methamphetamine are known to display bruxism, clenching of the jaw and grinding of the teeth, 
causing wear. Often patients do not feel any pain but seek dental treatment for cosmetic reasons 
(Donaldson et al., 2006). 
 
Figure 1.21: Dental caries due to methamphetamine abuse (Vearrier et al., 2012). 
 
1.2.5 Neurotoxic effects 
Neurotoxicity is an adverse effect on the structure or function of the central or peripheral nervous 
system caused by exposure to toxic substances called neurotoxins. These neurotoxic effects can 
range from short-term to permanent changes. In serious cases neurotoxicity can result in neuron 
loss and changes to brain structure. Neurotoxicity is associated with a number of disorders 
including behavioural problems, deficit regulation of emotion, impaired intelligence and 
depression (Cunha-Oliveira et al., 2008).  
Methamphetamine is a neurotoxin which, in high doses, causes the lasting depletion of the 
monoamines dopamine, serotonin, adrenaline and noradrenaline and damage to nerve terminals 
and cell bodies. While not completely understood, the neurotoxic effects of methamphetamine are 
believed to stem from interaction with the dopaminergic and serotonergic systems. Implicated in 
the neurotoxicity of methamphetamine are oxidative stress, excitotoxicity, hyperthermia, 
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mitochondrial dysfunction, inflammation and endoplasmic reticulum induced apoptosis (Cadet et 
al., 2007). 
1.3 Neurons and neurotransmitters 
1.3.1 The neuron 
The principal components of the nervous system, the neurons or nerve cells sense changes in the 
environment, then communicate these changes to other neurons and stimulate the body‟s response. 
The neuron is comprised of two parts: the cell body or soma, which contains the cell nucleus and 
organelles, and the neurites, numerous thin tubes radiating away from the cell body (Figure 1.31). 
The neurites are made up of multiple dendrites, and the axon, which is usually singular, branching 
and travels over great distances (Brown et al., 2007), for example, the sciatic nerve which runs 
from the base of the spine to the big toe (Encyclopaedia Britannica, 2014).  
 
Figure 1.31: The basic structure of a neuron consisting of the cell body or soma, the axon and 
dendrites (adapted from Brown et al., 2007). 
 
The synapse is the site where the end of an axon, or axon terminal, comes into contact with and 
passes information to other neurons. At the synapse, information in the form of electrical impulses 
is converted into a chemical signal that crosses the space between the neurons, called the synaptic 
cleft. These chemical signals, known as neurotransmitters of which there are several different 
types, activate receptors on the receiving or post-synaptic neuron creating a response or further 
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propagation of the electrical signal (Bear et al., 2007). Of these neurotransmitters, the most 
important are dopamine, serotonin and glutamate. 
 
1.3.2 Dopamine 
Dopamine is a catecholamine neurotransmitter within the CNS, where it controls a number of 
functions such as cognition, emotion, locomotion, endocrine regulation and reward processes. 
Dopamine is also active in the peripheral nervous system (the nerves and ganglia outside the CNS), 
with roles including catecholamine release, hormone secretion and the regulation of renal, heart 
and gastrointestinal function (Missale et al., 1998). Dopamine has been associated with disorders 
such as schizophrenia and Parkinson‟s disease and is known to be involved in the neurotoxicity of 
methamphetamine and a number of other drugs (Salamone et al., 2005).  
Accounting for less than 1% of the total neuronal population (Arias-Carrión et al., 2010), 
dopaminergic neurons are localized in the mesolimbic, mesocortical and nigrostriatal pathways 
(Schep et al., 2010) (Figure 1.32). These pathways encompass the nucleus accumbens, amygdala, 
hippocampus and striatum (Völlm et al., 2004), which are involved in emotion, motor control and 
reward (Schep et al., 2010). There are five subtypes of dopaminergic receptors. Two are D1-like 
receptors (D1 and D5) which are coupled to the G protein, Gs, and activate adenylyl cyclase. The 
other receptors are D2-like (D2, D3 and D4) and are G protein coupled receptors that act to 
activate potassium ion channels and inhibit adenylyl cyclase (Missale et al., 1998). The receptors 
have a similar distribution to the dopaminergic neurons (Arias-Carrión et al., 2010). 
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Figure 1.32: The dopamine (yellow) and serotonin (red) pathways through the brain. Some 
functions of each neurotransmitter are listed (NIDA, 2008). 
 
Dopamine is produced in a two step process. The rate limiting enzyme tyrosine hydroxylase 
converts the amino acid tyrosine to L-3,4-dihydroxyphenylalanine (DOPA), which then undergoes 
decarboxylation to dopamine (Figure 1.33; Daubner et al., 2011). After synthesis, dopamine is 
stored in presynaptic vesicles until release. Under normal physiological conditions dopamine is 
released from the pre-synaptic neuron into the synapse in response to relevant stimuli. Once in the 
synapse it diffuses in the extracellular fluid and activates its receptors (Arias-Carrión et al., 2010). 
Dopamine is cleared from the synapse as a result of reuptake via the dopamine transporter (DAT) 
and is metabolised by monoamine oxidase (MAO) (Riddle et al., 2006).  
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Figure 1.33: The dopamine biosynthesis pathway. Phenylalanine is converted to tyrosine by 
phenylalanine hydroxylase, tyrosine to DOPA by tyrosine hydroxylase, and DOPA to dopamine by 
aromatic acid decarboxylase. Dopamine is able to undergo further reactions to produce the 
catecholamines norepinephrine and epinephrine (Daubner et al., 2011). 
 
1.3.3 Serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) has a wide range of functions, including regulation of 
the sleep/wake cycle, learning, appetite and aggression. In the brain, serotonin acts as a 
neurotransmitter and is involved in emotional responses, movement and the reward system (Homer 
et al., 2008). The serotonergic system is one of the most diffuse, reaching almost every part of the 
CNS, but is mostly concentrated in the cerebral cortex, limbic structures, basal ganglia and 
brainstem (Figure 1.34) (Kranz et al., 2010). 
The amino acid tryptophan is converted in a two-step process to serotonin, involving the enzyme 
tryptophan hydroxylase, which is considered the rate-limiting enzyme. Serotonin is then stored in 
presynaptic vesicles until release into the synaptic cleft upon depolarisation. Serotonin can bind to 
post-synaptic serotonin receptors or to auto-receptors which act as negative feedback against 
further serotonin release. Reuptake of serotonin from the synapse is performed by the serotonin 
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transporter (SERT) located on the presynaptic neuron. Metabolism of serotonin occurs by MAO to 
produce 5-hydroxyindoleacetic acid or 5-HIAA (Figure 1.34) (Mohammad Zadeh et al., 2008). 
 
Figure 1.34: A serotonergic synapse showing the synthesis, storage, release, metabolism and 
reuptake of serotonin (Mohammad Zadeh et al., 2008). 
 
1.3.4 Glutamate 
Glutamate is the principal excitatory neurotransmitter and is ubiquitously distributed throughout 
the brain. Glutamate is important in the synthesis of proteins and peptides including glutathione 
(Fonnum, 1984). Due to its role in neuronal plasticity, glutamate is also involved in learning and 
memory functions. While glutamate is essential to brain function, excessive glutamate release has 
been implicated in neurotoxicity (Nakanishi, 1992). 
Glutamate can be synthesised from a number of different precursors: glutaminase can convert 
glutamine, aspartate aminotransferase converts 2-oxoglutarate and aspartate, and ornithine δ-
aminotransferase converts 2-oxoglutarate (Fonnum, 1984). Like dopamine and serotonin, 
glutamate is stored in vesicles after synthesis and is released upon depolarization by a calcium-
dependent mechanism. It may also be released in a non-calcium dependent process by reverse 
operation of the glutamate transporters, responsible for glutamate reuptake from extracellular 
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space. This occurs when the sodium and potassium ion gradient across the membrane is reduced in 
situations such as ischemic stroke (Meldrum, 2000).  
Until recently glutamate was thought to exclusively activate glutamate-gated cation channels called 
ionotropic glutamate receptors such as N-methyl-D-aspartate (NMDA) receptor. It has now been 
determined that glutamate also acts through metabotropic receptors bound to a G protein. It is the 
Ca
2+
 permeability of NMDA that is responsible for the neuronal plasticity and the neurotoxic 
properties of glutamate (Nakanishi, 1992). 
 
1.4 Neurotoxicity of methamphetamine 
Administration of methamphetamine causes damage to the dopaminergic and serotonergic nerve 
terminals, as well as some cell body degeneration. While the areas vulnerable to dopaminergic 
toxicity are relatively few (the striatum, frontal cortices and subcortical areas) (Oh et al., 2005), the 
areas susceptible to serotonergic damage are numerous and include the hippocampus, nucleus 
accumbens, amygdala, caudate nucleus and cingulate cortex (Panenka et al., 2012). Although the 
exact mechanisms are still unclear, there is agreement on the involvement of monoamine release, 
excitotoxicity, hyperthermia, free radical formation and oxidative stress (Figure 1.41).  
 
Figure 1.41: Pathways involved in methamphetamine neurotoxicity that lead to apoptosis and 
terminal degeneration in neurons (Cadet et al., 2007). 
 
13 
 
With prolonged use, methamphetamine causes a significant depletion of monoamines, dopamine 
and serotonin, an effect which has been shown to last several years after abstinence in primates 
(Friedman et al., 1998). Initially, methamphetamine causes an increase in the extracellular 
concentrations of dopamine and serotonin by stimulating their release from presynaptic terminals 
and preventing their reuptake or breakdown. This is achieved by disrupting several points in the 
monoamine release and reuptake pathway (Figure 1.42) (Riddle et al., 2006).      
             
Figure 1.42: Mechanisms whereby methamphetamine causes the release of dopamine and 
catecholamines from neuronal terminals into the synapse: (i) methamphetamine (triangles) enters 
the cell via diffusion or (ii) by dopamine transporters; (iii) methamphetamine reverses transport of 
dopamine (circles) from the vesicles to the cytosol; and (iv) and promotes the expression of 
tyrosine hydroxylase, increasing dopamine production; (v); decreases the expression of dopamine 
transporters at cell membrane; and (vi) inhibits monoamine oxidase activity (Schep et al., 2010). 
 
Due to its structural similarity to the monoamines, methamphetamine acts as a substrate for the 
membrane-bound dopamine and serotonin transporters (DAT and SERT), and is transported into 
the cytosol (Cho, 1990). Methamphetamine can also enter the cell via diffusion (Schep et al., 
2010). Once inside, methamphetamine causes reversal of the vesicular monoamine transporter 
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(VMAT-2), responsible for the storage of dopamine and serotonin in vesicles by reducing the pH 
of the vesicle. This compromises the ability of VMAT-2 to sequester monoamines (Panenka et al., 
2012), resulting in the displacement of the monoamines to the cytoplasm, where they are at risk of 
auto-oxidation. Methamphetamine is also responsible for the blockage of further uptake into the 
vesicles (Carvalho et al., 2012) and the redistribution of VMAT-2 to an as-yet unidentified cellular 
location (Panenka et al., 2012).  
The build-up of monoamines in the cytosol is further enhanced by the inhibition of the enzyme 
monoamine oxidase (MAO). MAO is present on the outer mitochondrial membrane and is 
responsible for monamine catabolism in presynaptic terminals (Panenka et al., 2012).  
 
Methamphetamine further increases the concentration of dopamine by promoting its synthesis 
through the up-regulation of tyrosine hydroxylase, the enzyme which catalyses the transformation 
of the dopamine precursor, tyrosine, into dopamine (Cunha-Oliveira et al., 2008). However, with 
chronic use of methamphetamine this effect is reversed, reducing the activity of tyrosine 
hydroxylase as well as the enzyme tryptophan hydroxylase involved in serotonin production 
(Hotchkiss, 1980).  
 
The binding of methamphetamine to the monoamine transporters causes the reverse transport of 
dopamine and serotonin into the synapse, where they are able to activate the postsynaptic receptor 
causing hyperstimulation. The reversal of the transporters is thought to occur through a facilitated 
exchange process, by which the inward transport of methamphetamine increases the inward facing 
binding sites for monoamine efflux (Khoshbouei et al., 2004). Methamphetamine also prevents 
reuptake of the monoamines from the synapse by reducing the number of transporters at the cell 
membrane. This effect is more likely due to internalisation or phosphorylation than destruction 
(Riddle et al., 2006). This has been confirmed with the finding that protein kinase C (PKC) activity 
increases with methamphetamine administration and can lead to phosphorylation of DAT 
(Khoshbouei et al., 2004).  
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Methamphetamine enhances the formation of reactive oxygen species (ROS) which cause damage 
to amino acids, phospholipids and nucleic acids (Cunha-Oliveira et al., 2008). The released 
dopamine is a potential source of ROS, as dopamine can undergo auto-oxidation via the Fenton 
reaction, using iron as a co-factor. Dopamine is also thought to be oxidised to dopamine quinones 
which can be converted to toxic radicals through redox cycling (Thrash et al., 2009). While the 
mechanisms are less well known, serotonin toxicity is also believed to be mediated by free radicals 
(Barr et al., 2006). 
The involvement of ROS has been confirmed by reports of increased oxidised and reduced 
glutathione levels after methamphetamine treatment (Gluck et al., 2001). Glutathione protects 
against oxidising environments by acting as a reducing agent and an antioxidant (Deneke et al., 
1989). Furthermore, mice over-expressing the antioxidant enzyme CuZn superoxide dismutase 
show reduced neurotoxicity (Gluck et al., 2001).  
 
The mitochondria present another source of intracellular ROS. Mitochondrial ROS are generated 
as a result of ATP production. The electron transport chain, located on the inner mitochondrial 
membrane, produces ROS as a side product during ATP formation. Methamphetamine is also 
known to inhibit complexes within the electron transport chain, increasing free radical production. 
The hydrogen peroxide produced during the breakdown of dopamine via MAO also interferes with 
electron transport chain activity. Electron transport chain complexes II and III seem to be the most 
affected, showing rapid inhibition within 1 hour of methamphetamine administration (Brown et al., 
2003). Using an infusion of methamphetamine and the complex II inhibitor malonate, Brown and 
colleagues (2005) found lasting depletions of dopamine in the striatum greater than that seen with 
malonate alone. The breakdown of the electron transport chain and associated depletion of ATP 
initiates transcription factor p53. p53, responsible for the apoptotic death pathway, has been shown 
to accumulate following methamphetamine administration (Thrash et al., 2009). 
Decrease in ATP production can also lead to excitotoxicity, a process of neuronal death brought 
about by excessive and prolonged activation of the excitatory amino acid (EAA) receptors. Release 
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of glutamate, the major mammalian excitatory amino acid, is enhanced by methamphetamine 
administration and is responsible for its excitotoxic effect (Pederson et al., 2000). The increase in 
glutamate availability causes over stimulation of the N-methyl-D-aspartate (NMDA) receptor which 
is spatially linked to neuronal nitric oxide synthase (nNOS), which can produce the nitric oxide 
involved in neuronal degeneration (Lau et al., 2010).  Glutamate release is highly dependent on 
calcium influx which is mediated by the activation of ionotropic and metabotropic glutamate 
receptors.  High calcium levels can lead to activation of kinases, proteases and lipases, the 
breakdown of cytoskeletal proteins and the production of free radicals and resulting DNA damage 
(Quinton et al., 2006). 
 
Much of the intracellular calcium released by excitotoxicity enters the mitochondria where it 
causes de-energisation and the release of pro-apoptotic factor cytochrome C (Lankiewicz et al., 
2000). Calcium influx can also activate ROS formation, further inhibiting mitochondrial function 
(Brown et al., 2003). The involvement of glutamate excitotoxicity in mitochondrial damage has 
been confirmed by the administration of NMDA antagonist MK-801, which prevented the decrease 
of complex II-III activity induced by methamphetamine (Brown et al., 2005). Whether the 
mitochondria recovers after an excitotoxic injury determines the mechanism by which the neuron 
dies. Necrosis occurs immediately after glutamate exposure and is associated with loss of 
mitochondrial function. Death of surviving neurons with functional mitochondria occurs by 
apoptosis and is a delayed process (Ankarcrona et al., 1995). The hyperthermic response brought 
on by methamphetamine may also contribute to the decreased activity of the electron transport 
chain (Brown et al., 2003). 
 
While not directly responsible for the neurotoxicity of methamphetamine, hyperthermia greatly 
potentiates neurotoxic effects. Lowering the ambient temperature using substances such as 
haloperidol, diazepam and MK-801, is effective in preventing neurotoxicity, however, this effect 
was negated with an increase an ambient temperature. Importantly, methamphetamine treatment is 
able to produce neurotoxic damage without a hyperthermic response and in hypothermic animals. 
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While the exact mechanisms of methamphetamine-induced hyperthermia are unknown, the release 
of monoamines is thought to be involved (Albers et al., 1995). Also implicated in the hyperthermia 
response are vasoconstriction produced by methamphetamine release of noradrenaline and 
interleukin-1 (IL-1) produced during microglia stimulation (Bowyer et al., 1994). 
 
1.41 Metabolism of methamphetamine 
Methamphetamine has a relatively long half-life of approximately 12 hours in humans (Cho, 1990) 
and undergoes a number of metabolic reactions within the liver, mainly involving the enzyme 
CYP2D6 (Figure 1.43; Schep et al., 2010). Primary reactions include aromatic hydroxylation, N-
demethylation and aliphatic hydroxylation, although, the extent of these reactions varies widely 
with species (Caldwell et al., 1972). Excretion is mainly via the urine and to a small extent by 
sweat and in the faeces (Schep et al., 2010). In man, methamphetamine is not well metabolised 
with 30-40% of the drug being eliminated unchanged compared to 15% in the rat. Other 
metabolites found in urine include 4-hydroxymethamphetamine (15 %), hippuric acid (5 %), 
amphetamine (2-3 %) norephedrine (2 %) and 4-hydroxynorephedrine (1-2 %) (Caldwell et al., 
1972). 
 
1.42 Methamphetamine addiction 
Methamphetamine is often described as the most addictive drug and can cause dependence after 
the first use. While methamphetamine is highly addictive, addiction is a long term consequence 
and results from changes in brain chemistry that compromise top-down control (Salo et al., 2006). 
It is the euphoria experienced after intake to which users become addicted. This effect comes about 
due to the stimulation of the mesolimbic and nigrostriatal reward pathways by the release of 
dopamine (Thrash et al., 2009). 
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Figure 1.43: The main metabolic pathways of methamphetamine: (i) aromatic hydroxylation, (ii) 
N-demethylation, (iii) β-hydroxylation, (iv) oxidative deamination (v) side-chain oxidation. In 
man, the main pathways are (i) and (ii) resulting in 4-OH methamphetamine and amphetamine 
respectively (Schep et al., 2010).  
When questioned about their reasons for taking methamphetamine or relapsing to 
methamphetamine, 27% of the study participants claimed to take the drugs impulsively with 31% 
being unable to stop once they began preparation. Cravings were a highly rated motivation and 
27% claimed to use drugs to lessen withdrawal symptoms (Newton et al., 2009). Withdrawal is 
associated with disturbances of cognition and mood characterised by depression, anxiety, cravings 
and increased sleeping and eating. These symptoms begin to lessen within 7 to 10 days of 
abstinence (Berman et al., 2008).   
The work of Day and colleagues (2008) revealed that mice which had been repeatedly exposed to 
methamphetamine showed a decreased rate of glutamate release indicating presynaptic depression 
at corticostriatal terminals. Withdrawal from the drug did not return glutamate to normal levels; 
however, the effect was reversed upon the re-administration of the drug. Similarly, Bamford et al. 
(2008) found a reduction of acetylcholine causing corticostriatal terminal depression which was 
reversed with methamphetamine re-administration. These studies provide new insight into the 
changes within the brain and account for some of the physiological components of addiction and 
19 
 
tolerance to the pleasurable effects which can develop after repeated use. As methamphetamine 
causes a sustained depletion of dopamine, users have difficultly feeling any pleasure other than that 
gained using the drug (NIDA, 2013). 
 
The neurotoxic effects of methamphetamine severely impact the mechanisms of cellular function 
such as the mitochondrial electron transport chain. This would result in changes to the biochemical 
make up of the cell. 
1.5 Metabolomics 
The metabolome, as first described by Oliver and colleagues (1998), is the set of all low-
molecular-weight compounds, or metabolites, present within a cell or organism, that participate in 
metabolic reactions. As the metabolome is the downstream product of gene expression, it shows 
more diversity in physical and chemical properties than the transcriptome (RNA) or proteome 
(protein) (Dunn et al., 2005). Any changes in the transcriptome or proteome, would consequently 
be expected to be amplified in the metabolome (Goodacre et al., 2004). Metabolomics, therefore, is 
the study of metabolites and how they are affected by genetic modification, stimuli or changes in 
the environment. Metabolomics aims to identify and measure all metabolites in a system 
(Almstetter et al, 2012). 
Although metabolomics has been in use for a number of years, metabolomic studies using 
mammalian cells are limited. A review of the literature available shows that cell culture analysis, 
while on the rise, still lags behind body fluids metabolomics (Figure 1.51; Cuperlović-Culf et al., 
2010). While they offer more limited metabolic functions, clonal cell lines are often preferred over 
primary cells in metabolomic studies for their availability, simple handling and reduced variability 
(Leon et al., 2013). In spite of this, the application of metabolomics to cell lines has been impeded 
by several factors, key among them being the fact that the composition of the medium, seeding 
density and age of the cells can all influence the metabolome. Common quenching processes, such 
as the use of methanol, can cause damage to cell membranes, leading to leakage of metabolites into 
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the extracellular fluid (Leon et al., 2013) and extraction processes are time-consuming 
(Cuperlović-Culf et al., 2010). Despite these limitations, mammalian cell metabolomics has proved 
useful in numerous areas including biomarker identification, drug testing, pharmaceutical research 
and toxicology (Leon et al., 2013). 
 
Figure 1.51: Comparison of the number of publications (1999-2008) available on various 
applications of metabolomics. Blue, cell culture/line; red, blood/serum and green, urine. Search 
was performed in PubMed using the keywords outlined in the legend (Cuperlović-Culf et al., 
2010). 
 
Metabolomics provides a snap shot of a cell‟s activity at a certain point in time and under given 
conditions. In order to achieve this, metabolism must be stopped as quickly as possible to avoid 
compositional changes in the metabolome. In addition, the analysis ideally requires high recovery, 
reproducibility and sensitivity and a definite identification and quantification of metabolites (De la 
Luz-Hdez, 2012).  
As metabolites are very labile and diverse, there is currently no single analytical system that is able 
to detect and quantify all of the metabolites within an organism (Desbrosses et al., 2005). The most 
commonly used systems are nuclear magnetic resonance (NMR) spectroscopy and gas- or liquid 
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chromatography (GC; LC) coupled with mass spectrometry (MS). A comparison of various aspects 
of these technologies is given in Table 1.5 (Mayr, 2008).  
NMR detects the nuclear spin of molecules with uneven numbers of protons and neutrons such as 
1
H, which is present in high abundance in organic compounds. NMR is therefore able to detect a 
wide range of metabolites, and is also highly reproducible and robust. NMR has the added 
advantages of not destroying the sample during analysis and has the ability to perform in-vivo 
analysis. However, NMR does have poor sensitivity when compared with mass spectrometry 
(Mayr, 2008) and many functional groups are proton-deficient making identification challenging 
(Villas-Boas et al., 2004). 
GC-MS is a popular alternative to NMR due to its sensitivity. This technique separates compounds 
by GC, based on their affinity for a gas or solid phase, before they undergo ionization, 
fragmentation and detection in the MS (Desbrosses et al., 2005). Metabolites are identified by 
comparison of retention time with known standards. GC-MS is most useful in the analysis of 
volatile compounds, meaning that non-volatile metabolites (e.g. amino acids, sugars, fatty acids 
and other polar metabolites) must be made thermally stable through chemical derivatisation before 
being analysed by GC-MS (Dunn et al., 2005). This process is time-consuming and can introduce 
confounding factors to the chromatogram (Halket et al., 2005). A key draw back of GC-MS is that 
samples are destroyed during analysis (Dunn et al., 2005). 
Functionally, LC-MS is similar to GC-MS, however LC separates metabolites based on their 
affinity for a liquid or solid phase. LC-MS is suited to the analysis of non-volatile compounds that 
are soluble in solution. An advantage of LC-MS is the ability to directly analyse many polar 
metabolites without derivatisation (De la Luz-Hdez et al., 2012). 
 
 
 
22 
 
Table 1.5: A comparison of NMR, GC-MS and LC-MS in relation to metabolomics analysis 
(Mayr, 2008). 
 
 
1.6 Gas Chromatography-Mass Spectrometry 
GC-MS is well established in mammalian cell metabolomics research (Leon, 2013). For this 
reason, as well as its good sensitivity, separation power and ability to be applied to a wide range of 
metabolites (Mayr, 2008), it is the platform utilised in the following experiments.  
The GC consists of a gas supply, an injector, flow and pressure regulators and a column contained 
within an oven (Figure 1.61). The sample is injected into the injector site, which is maintained at a 
set temperature, and is evaporated. A carrier gas flows into the injector port at a constant and 
controlled rate and carries the vaporised sample into the column. The column is usually an open 
tubular, narrow bore fused silica tube to which the stationary phase is chemically bound.  Within 
the column, the evaporated compounds are separated according to their distribution between the 
solid and gaseous phases. After separation, the sample is transferred to the MS (Villas-Boas et al., 
2007). 
The MS performs the functions of analysing, detecting and determining structural information of 
the sample. It consists of an ion source, mass analyser, detector and data system (Figure 1.61). The 
most common ionization method used in GC-MS is electron impact. The ion source emits 
energized electrons which collide with the sample molecules, producing ions in a fragmentation 
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pattern highly unique to that compound. The ions are transferred to a vacuum for determination of 
the mass-to-charge ratio (m/z) in the mass analyser. The quadrupole mass analyser is commonly 
used in the GC-MS system for its simplicity and reliability. It consists of four parallel rods with a 
voltage supplied. The voltage creates a cylinder through which the molecules pass to reach the 
detector. Only ions within a certain m/z range are allowed to pass through the entire cylinder; 
others hit the rods and are neutralised. The detector measures the current or the number of ions 
passing through as a function of time. This information is then read by the data system which 
processes the information (Villas-Boas et al., 2007). 
 
Figure 1.61: Overview of the GC-MS instrument. (Adapted from Dunnivant and Ginsbach, 2008) 
 
There are seven main steps involved in GC-MS metabolomics. Firstly, quenching of the sample to 
prevent further metabolic activity. This usually involves the separation of cells from the culture 
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medium and detachment from the culture plates which can lead to cell leakage. The quenching 
process must be rapid and avoid metabolite destruction or modification (Desbrosses et al., 2005).  
Secondly, metabolites must be extracted from the cells in an unbiased manner. This can be difficult 
due to the range of metabolite polarities. Again, extraction must aim to minimise metabolite 
changes (Dettmer et al., 2011). Next, the samples must undergo derivatisation to create thermal 
stability for the GC-MS analysis. The samples are then separated and detected by GC-MS and, 
lastly the chromatographic output is analysed by software to identify fragmentation patterns using 
reference libraries (Desbrosses et al., 2005). 
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1.7 Aims 
The impact of methamphetamine‟s neurotoxic effects is evident in the altered biochemistry of the 
neuronal cell. The GC-MS metabolomics method provides an insight into these changes through 
the identification and quantification of intra- and extracellular metabolites. 
The aims of this project were to utilise an established in-vitro neuronal cell culture model to 
investigate cellular mechanisms of methamphetamine neurotoxicity, specifically: 
1) To demonstrate, measure and compare the decrease in neuronal viability after exposure to a 
range of methamphetamine concentrations; 
2) To analyse the metabolite profile of neuronal cells after administration of a range of 
methamphetamine concentrations, and; 
3) To study the changes to the metabolite profile of neuronal cells over time after administration of 
a toxic dose of methamphetamine 
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2. Materials and methods 
2.1 Materials 
2.11 Chemicals and kits 
D-sorbitol-6-
13C, Dulbecco‟s modified Eagle‟s medium (DMEM), foetal calf serum, L-glutamine, 
methamphetamine hydrochloride, methoxyamine hydrochloride, n-alkanes (C10, C12, C15, C19, C22, 
C28, C32, C36), N-methyl-N-(trimethylsilyl)trifluroacetamide (MSTFA), penicillin/streptomycin 
solution, phosphate buffered solution (PBS), pyridine and trypsin-EDTA solution were all 
purchased form Sigma-Aldrich, (Sydney Australia) in the highest purity available. LDH assay was 
performed using a CytoTox 96 Non-Radioactive Cytotoxicity Assay kit purchased from Promega 
Corporation, (Sydney, Australia). LC-MS grade methanol and HPLC grade water were purchased 
from Fisher Scientific (Fair Lawn, USA). n-hexane (95%) was purchased from LabScan, (Gliwice, 
Poland). Carbon dioxide (CO2) (food grade) and helium (ultra-high purity) were obtained from 
BOC Gases, (Perth, Australia). 
2.12 Cells 
Cells used for all experiments were a B50 rat neuroblastoma cell line obtained through the 
European Collection of Cell Cultures and purchased from Sigma Aldrich. Cells were grown in 
75cm
2
 flasks (Corning, NY,USA) and maintained at 37
o
C in a humidified atmosphere of 95% air 
and 5% CO2 using a Thermo Scientific Heraeus Function Line incubator (Scoresby, Australia). 
2.2 Methods 
2.21 Cell culture 
B50 cells were maintained in DMEM (12 mL) supplemented with 5% foetal calf serum, 1% L-
glutamine and 1% penicillin/streptomycin. Cells were cultured until 70-80% confluent before 
being passaged or seeded onto 6-well plates for experimentation. Cells were dislodged from the 
flask for passaging by trypsinisation. This involved the removal of DMEM and the addition of 2 ml 
1 x trypsin-EDTA, incubation for 2 minutes at 37
o
C and 5% CO2 followed by inactivation of 
trypsin by the addition of DMEM containing the above supplements. Cells were then resuspended 
with fresh DMEM, aliquoted into new flasks and made up to 12 mL with DMEM. 
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Photos were taken using a Moticam 2300 camera (Motic Instruments Inc., Hong Kong) and Motic 
Images Plus software (v2.0) in combination with an Olympus CKX41 microscope (Tokyo Japan) 
immediately prior to harvesting to record morphological differences between control and 
methamphetamine-treated cells. 
2.22 Cell counting 
One well on each plate was reserved for cell counting. In this process, which was conducted at the 
same time as harvesting (2.24), the medium was removed from the well and 500 µL of trypsin 
added to detach cells from the plate. The plate was incubated at 37
o
C for 5 minutes before the 
addition of 2 mL of DMEM to terminate trypsinisation. An aliquot of 10 µL was transferred to a 
haemocytometer and counted using an Olympus inverted research microscope (model IMT-2, 
Tokyo, Japan.). The cells in the four corner squares were counted, excluding those on the outside 
borders. The average of these counts was used to estimate the number of cells per well for each 
plate. 
The Trypan blue exclusion test was conducted during the cell counting process. In this assay, the 
media was removed and 500 µL trypsin added to a single well as per the counting method above. 
After 5 minutes incubation at 37
o
C, 2 mL of fresh DMEM was added. A 2 mL aliquot of the cell 
suspension was centrifuged at 150 x g for 3 minutes and the supernatant discarded. The resulting 
pellet was resuspended in 1 mL of PBS. Equal amounts (10 µL) of the cell suspension and 0.4% 
Trypan blue were mixed in a 96-well plate and applied to the haemocytometer for counting. The 
unstained (viable) and blue stained (dead or damaged) cells were counted separately and used to 
estimate the percentage cell viability for each experimental condition. 
2.23 LDH Assay 
A lactate dehydrogenase (LDH) assay is a useful way to measure cytotoxicity mediated by 
chemicals. Using colorimetric methods, the assay quantitatively measures lactate dehydrogenase, 
an enzyme released upon cell lysis. Due to a coupled enzymatic reaction, the amount of colour 
produced is directly proportional to the amount of LDH present (Promega, 2012).  
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Before experimental use, the method was optimised for use with B50 cells and Dulbecco‟s 
modified Eagle‟s medium to determine correct dilution factors. 
A 500 µL sample of media was collected from each well and placed in separate tubes before being 
centrifuged at 1092 x g and 4
o
C for 5 minutes. These samples were diluted 1:50 with DMEM, 
vortexed and kept on ice.  
6-well plates containing cells and remaining media then underwent a freeze-thaw lysis process: 30 
minutes at -80
o
C followed by a 15-minute incubation at 37
o
C. During freeze-thaw lysis, the cells 
break open as ice crystals formed during the freeze stage contract when thawing (Tansey, 2006). 
Cells were scraped from each well into the media and both media and cells collected into tubes. 
The tubes were vortexed and centrifuged at 1092 x g for 4 minutes. Each sample was diluted 1:100 
with DMEM, vortexed and placed on ice. 
Triplicate media and cell-media lysis samples was transferred to a 96-well plate at 50 µL per well. 
Triplicates of media and treatment blanks were also included to ensure no background absorbance 
or interaction of methamphetamine with the assay substrate. The assay substrate mix was added 
(50 µL) to each well and the plate was covered and incubated at room temperature for 30 minutes. 
After the incubation period, the assay stop solution was added (50 µL) and, after ensuring the 
absence of bubbles, the absorbance was read at 490 nm using an iMark microplate absorbance 
reader (Bio-rad; Gladesville, Australia). 
2.24 Harvesting 
The harvesting process is a crucial step in metabolomics studies. In order to stop enzymatic 
activity, the samples must be quenched as quickly as possible after the treatment period. Without 
this quenching step, degradation of the metabolites may occur and the composition of the sample 
may alter. Harvesting also acts to detach adherent cells from culture plates (Dettmer et al., 2010). 
From each plate, a medium sample of 40 µL was taken from five wells, pooled in a 1.5 mL tube 
and stored on ice. Any remaining medium from these wells was then discarded. Cold PBS was 
used as a cell wash buffer with the addition of 1 mL to each well. PBS was carefully removed and 
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discarded to avoid disturbing the cells. To quench the cells, a further 100 µL of cold PBS was 
added and cells scraped into the buffer using a plastic cell scraper. The contents of the wells was 
collected into a single 1.5 mL tube and stored on ice until freezing. All samples were transferred to 
-80
o
C until frozen, after which they were freeze-dried using a Labconco FreeZone 2.5 Plus (Kansas 
City, USA) and stored at -80
o
C until extraction. 
2.25 Extraction 
For metabolomic analysis to be successful, efficient metabolite extraction is required. Extraction is 
the process by which metabolites are released from the cell sample and separated from other, 
undesired, compounds such as proteins (Sana et al., 2007).  
An extraction solution was prepared by dissolving the internal standard of 
13
C6-sorbitol in LC-MS 
grade methanol at 2.6 µg/mL. 500 µL of extraction solution was added to each cell and media 
sample. The cell samples were vortexed and the contents transferred to lysis tubes. The contents of 
the cells were extracted using the Precellys 24 lysis and homogenisation tissue lyser (Bertin 
Technologies, Aix-en-Provence, France), run for two 20-second cycles at 6500 rpm. 
Both the medium and cell samples were centrifuged at 16,100 x g for 10 minutes and 300 µL of the 
resulting supernatant transferred to fresh 1.5 mL tubes. The volume was reduced using the 
Eppendorf Concentrator Plus rotary vacuum concentrator (North Ryde, Australia) for 90 minutes 
to reduce the volume by at least 75% to facilitate freezing. 300 µL HPLC grade water was added to 
each sample and tubes were frozen at -80
o
C. Once frozen, the samples were freeze-dried and stored 
at -80
o
C until derivatisation. 
2.26 Derivatisation 
In order to improve the sensitivity and specificity of analysis using gas chromatography, a 
derivatisation step is required. This enables the analysis of non-volatile compounds and improves 
separation on GC columns (Almstetter et al., 2012). The derivatisation method used in this project 
is well-established (Abbiss et al., 2012). 
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A solution of 20 mg/mL methoxyamine hydrochloride in pyridine was prepared and 20 µL added 
to each extracted sample. By reacting with carbonyl groups to form oxime derivatives, 
methoxyamine acts as a protective agent, ensuring compounds are able to be derivatised (Sellers, 
2007). Using the Eppendorf Thermomixer comfort (North Ryde, Australia) samples were agitated 
at 1200 rpm and 30
o
C for 90 minutes. Samples were then centrifuged at 16,100 x g for 1 minute 
and 40 µL of MSTFA was added to each. The samples were further agitated at 300 rpm at 37
o
C for 
30 minutes. Each sample was transferred to a 2 mL GC vial, 100 µL standard insert and aluminium 
combination seal, and 5 µL of a mixture of n-alkanes in n-hexane were added. This alkane mixture 
(C10-C36, 0.625 mg/mL) is added to allow the calculation of a Kovat‟s index. 
2.27 Instrumental analysis 
The gas chromatography-mass spectrometry (GC-MS) system used for these experiments was an 
Agilent 6890 Series gas chromatograph with an Agilent 7683 autosampler and injector, coupled 
with an Agilent 5973 Series single quadrupole mass selective detector (Agilent Technologies, 
Santa Clara, USA) using an established metabolomic analysis method (Abbiss et al., 2012). The 
GC carrier gas was helium and a deactivated inlet liner with glass wool was used. The column used 
for analyte separation in these experiments was an Agilent FactorFour VF-5ms fused silica 
capillary column (30 m length x 0.25 mm internal diameter 0.25µm film thickness + 10 m EZ-
Guard; Agilent Technologies). 
The GC program was as follows: inlet temperature was set to 230
o
C and the oven had an initial 
temperature of 70
o
C. The temperature was ramped at 1
o
C per minute for 6 minutes and then 
increased a further 5.63
o
C per minute to reach a final temperature of 330
o
C, which was maintained 
for 10 minutes. The GC to MS transfer line was held at 330
o
C and the ion source was set to 230
o
C 
and 70 eV, with an 8-minute solvent delay. The detector performed a full scan for the mass range 
of m/z 45 to 600 at 1 scan per second. 
 
 
31 
 
2.28 Data analysis 
GC-MS data was imported into Analyzer Pro (v2.7.0; Spectral Works Ltd., Runcorn, United 
Kingdom). This program assigns peaks to the data and identifies metabolites by comparison with a 
target component library (Metabolomics Node, Murdoch University and National Institute of 
Standards and Technology (NIST) 2005), matching according to mass spectrum and retention 
index information. The results of this analysis were exported as a matrix into Microsoft Excel 
(v12.0; Microsoft Corporation, Redmond, USA) to allow for manual inspection and data clean-up. 
The Excel matrix was imported into The Unscrambler X (v10.1; CAMO, Oslo, Norway) to allow 
for comparison between samples. The matrix data was transformed by log10 before performing a 
principal component analysis, using non-linear iterative partial squares algorithm, cross validation 
and no rotation. For the dose curve and time course experiments, data was normalised to the total 
ion chromatogram (TIC) for each sample. 
2.3 Experiments 
2.31 LDH assay 
B50 cells were grown in 75cm
2
 flasks until 70-80% confluent before being seeded onto 6-well 
plates at 3 mL per well. Methamphetamine solution was prepared at 14.9 mg/mL 
methamphetamine hydrochloride in HPLC grade H2O and serially diluted to achieve the desired 
dose. After 24 hours incubation at 37
o
C and 5% CO2, cells were treated with 30 µL 
methamphetamine to reach final concentrations of 1 µm, 10 µM, 100 µM and 1 mM which were 
tested in triplicate. Three wells were used as a vehicle control using HPLC grade H2O. Plates were 
incubated for 48 hours and after the treatment period, LDH cytotoxicity assay was performed as 
described in 2.23. 
2.32 Dose curve 
To examine the influence of methamphetamine concentration on the neuronal metabolite profile, 
an experimental dose curve was conducted. A reduction in cell viability following exposure to 
methamphetamine at various concentrations has been well recorded within the literature. In 
neuronal cells, Stumm and colleagues (1999) found 1 mM methamphetamine led to approximately 
32 
 
50% reduction in viability after 96 hours exposure. Similar results were found by Shao and 
colleagues (2012), who found a 50% drop in the viability of endothelial cells compared to control 
after 48 hours exposure to methamphetamine. At methamphetamine concentrations below 0.125 
mM, little to no change in neuronal viability was reported after 24 hours incubation (Sinchai et al., 
2011). Using a range of concentrations would allow us to compare the metabolic changes 
occurring at toxic and sub-toxic doses of methamphetamine. 
Cells were grown in 75cm
2
 flasks until 70-80% confluent before being plated in 6-well plates. 
Methamphetamine solution was prepared at 14.9 mg/mL methamphetamine hydrochloride in 
HPLC grade H2O and serially diluted to achieve the desired dose. After 24 hours incubation at 
37
o
C and 5% CO2, cells were treated with 30 µL methamphetamine solution to final concentrations 
of 100 nM, 1 µM, 10 µM, 100 µM and 1 mM. Each concentration was tested in triplicate with an 
additional three plates used as controls with the addition of HPLC grade H2O. The plates were 
incubated for 48 hours before harvesting and this experiment was undertaken in duplicate.  
2.33 Time Course 
The biochemical changes over time due to methamphetamine administration were investigated 
using a time course experiment. Cells were cultured in 75cm
2
 flasks until 70-80% confluent, plated 
into 6-well plates and incubated for 24 hours at 37
o
C and 5% CO2. Methamphetamine solution was 
prepared at 14.9 mg/mL methamphetamine hydrochloride in HPLC grade H2O. Six plates were 
administered 30 µL of methamphetamine for a final concentration of 1 mM, with the remaining six 
kept as controls by adding HPLC grade H2O. At 6, 24 and 48 hours after drug administration, 
duplicate treated and control plates were harvested. This time course experiment was conducted in 
duplicate. 
 
 
 
 
33 
 
3. Results 
3.1 Cell viability testing 
To investigate the effect of methamphetamine dose on B50 neuroblastoma cells, cells were 
exposed to a range of methamphetamine concentrations (100 nM, 1µM, 10 µM, 100 µM and 1 
mM) for 48 hours. The photographic evidence of observed changes is shown in Figure 3.11. 
At 48 hours, all cells including controls displayed some indications of clumping or aggregation. 
The cells demonstrated little change in appearance from controls at concentrations below 100 µM. 
At 100 µM and 1 mM methamphetamine, the B50 cells showed excessive aggregation and retained 
little normal neuronal morphology.  
To determine if the morphological changes coincided with cell death, toxicity was quantified using 
a LDH cytotoxicity assay. B50 rat neuroblastoma cells were incubated with methamphetamine (1 
µM, 10 µM, 100 µM and 1 mM) for 48 hours and cytotoxicity compared to controls was 
determined by LDH assay (see 2.23). The results, expressed as percentage cytotoxicity are 
presented in Figure 3.12. The cytotoxicity of 1 mM methamphetamine (21.9% ± 4.8) was found to 
be considerably higher than the control (14.9% ± 1.6) while the lowest concentration tested, 1 µM, 
showed very little change from the control (15.3% ± 0.9). Conversely, the mid-range 
concentrations of 10 µM and 100 µM showed less toxicity than the control and 1 µM 
methamphetamine.  
As a comparison to the LDH method, Trypan blue exclusion was also used to assess cell viability. 
B50 cells treated with methamphetamine at a range of concentrations (100 nM, 1 µM, 10 µM, 100 
µM and 1 mM) were compared to control cells after 48 hours of exposure. The results, given as a 
percentage of the control, are shown in Figure 3.13. This shows a dose-dependent decrease in the 
viability of neuronal cells as compared to controls, with the viability of the highest concentration (1 
mM) being 69.9% ± 3.4 of the control.  
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Figure 3.11 Photographs of B50 cells after 48 hours of methamphetamine treatment at various 
doses:  A) control B) 100 nM C) 1 µM D) 10 µM E) 100 µM F) 1 mM. Photos were taken using a 
Moticam 2300 camera in combination with an Olympus CKX41 microscope at 100 x 
magnification. 
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Figure 3.12: Cytotoxicity of methamphetamine after 48 hours exposure to neuronal cells as 
measured by LDH assay. The percentage cytotoxicity of methamphetamine (concentration 1 µM, 
10 µM, 100 µM and 1 mM) to cultured neuronal cells compared to controls. % cytotoxicity 
represents mean ± standard error (n=3). Percentage cytotoxicity was calculated by comparing LDH 
release of medium samples taken from each concentration or control with its corresponding total 
cell fraction. 
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Figure 3.13: Cell viability after 48 hours exposure to methamphetamine as measured by Trypan 
blue exclusion testing. The viability of neuronal cells after methamphetamine exposure 
(concentrations 100 nM, 1 µM, 10 µM, 100 µM and 1 mM) compared to controls. Viability is 
given as a percentage of the control value. % viability represents mean ± standard error (n=4). 
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3.2 Dose curve 
The fact that methamphetamine causes neuronal death is well known, however, the biochemical 
response of cells to methamphetamine administration is less well documented. A dose curve 
experiment was undertaken to compare the changes occurring in the metabolome under 
administration of methamphetamine at toxic and sub-toxic doses from 100 nM to 1 mM. In order 
to compare the results from duplicate experiments, the data was normalized to the total ion 
chromatogram (TIC) for each sample.  
3.2.1. Intracellular metabolites 
Principal component analysis (PCA) is a common method for data mining in metabolomics 
analysis (Putri et al., 2013). The scores plot (Figure 3.21-A) shows the relationship between the 
treatment groups. Variance in the cell sample dataset is best described by principal component 1 
(PC-1), which explains 48%, while PC-2 explains 28%. The control samples grouped most closely 
with the 1 µM samples and separate from the higher concentrations, which grouped together. 
Triplicate samples at 100 nM methamphetamine were included as part of the experiment, but were 
excluded from analysis due to the large variance between the replicates.  
The loadings plot (Figure 3.21-B) identifies the metabolites which contribute most to the difference 
observed between samples. The loadings data was extracted from this plot and twelve metabolites 
which had the most impact on the variance between samples were chosen from the loadings plot 
for further study. The peak area at each concentration was then expressed as a percentage of the 
control. Figures 3.22 and 3.23 display the results of this analysis, showing the amino acids and 
other metabolites, respectively. 
A number of amino acids including L-isoleucine, showed a decrease in peak area as dose increased 
from 100 µM to 1 mM. L-proline followed a similar trend, with peak area increasing from 0.76 ± 
0.10 to 1.26 ± 0.07 between 1 µM and 100 µM before dropping below control at 1 mM. Overall, L- 
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Figure 3.21: Principal component analysis of GC-MS metabolomics data generated from B50 rat 
neuroblastoma cells following exposure to methamphetamine. Cells were incubated with or 
without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for 48 hours. (A) Scores plot, with 
sample groupings identified. (B) Loadings plot, showing metabolites and their influence on the 
sample groupings in (A). Data was deconvoluted, compounds identified and normalised to internal 
standard prior to multivariate analysis.  
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Figure 3.22: Changes in intracellular amino acids of B50 cells with dose of methamphetamine 
identified by PCA as contributing most to the variance observed between samples. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of 48 
hours. Amino acids were chosen from the GC-MS metabolite data, normalised to total ion 
chromatogram and presented as a percentage of the control value. Peak area is mean ± standard 
error. n=3 
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Figure 3.23: Changes in intracellular metabolites of B50 cells with dose of methamphetamine 
identified by PCA as contributing most to the variance observed between samples. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of 48 
hours. Metabolites were chosen from the GC-MS metabolite data, normalised to total ion 
chromatogram and presented as a percentage of the control value. Peak area is mean ± standard 
error. n=3 
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leucine, L-threonine and L-valine showed very little change from the controls. Only L-serine 
showed an upwards trend, with a dose-dependent increase in peak area. 
The “other” metabolite group displayed more variety in trends compared to the amino acids. Of all 
the metabolites analysed, galactose had the greatest increase in peak area with a substantial 
increase from 0.13 ± 0.01 at 1 µM to 333.64 ± 2.68 at 10 µM, remaining high until a slight 
decrease at 1 mM. Cholesterol and glycerol 3-phosphate levels decreased to below controls at 1 
mM methamphetamine. γ-aminobutyric acid (GABA) showed a similar trend, except instead of 
decreasing at 1 mM, GABA levels increased sharply. Levels of N-acetylglutamate slowly 
increased from 3.15 ± 1.17 to 3.79 ± 0.71 between 1 µM and 100 µM and sharply decreased to 1.56 
± 0.95 at 1mM of methamphetamine. Octadecenoate levels increase from 0.66 ± 0.15 at 1 µM to 
1.31 ± 0.21 at 10 µM then gradually declined. 
3.2.2 Extracellular metabolites 
In order to have a full understanding of metabolic changes, it is important to consider both the 
intracellular metabolome, the metabolites within the cell, and the extracellular metabolome, 
consisting of the metabolites present within the culture medium. Changes within the cell may be 
reflected in the extracellular metabolome, and there may also be the exchange of metabolites 
between cells and the surrounding medium due to uptake or excretion (Leon, 2013).  
A PCA was generated from the GC-MS data of media samples and is presented in Figure 3.24. The 
scores plot (A) shows clear differences between the treatment groups. The variance between 
groups is best explained by PC-1 (43%) and PC-2 (20%). Compared to the cell PCA in Figure 
3.21, there appears to be a greater overlap between samples treated with low and high 
concentrations of methamphetamine. The loadings plot (B) was used to identify the metabolites 
representing the greatest source of variance between the groupings, which were further analysed 
and plotted as dose curves (Figures 3.25, 3.26 and 3.27). Triplicates samples at 100 nM 
methamphetamine were included as part of the experiment, but were excluded from analysis due to 
the large variance between the replicates. 
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Figure 3.24: Principal component analysis of GC-MS metabolomic data generated from medium 
obtained from B50 rat neuroblastoma cells following exposure to methamphetamine. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of for 48 
hours. (A) Scores plot, with sample groupings identified. (B) Loadings plot, showing metabolites 
and their influence on the sample groupings in (A). Data was deconvoluted, compounds identified 
and normalised to internal standard prior to multivariate analysis.  
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Figure 3.25: Changes in extracellular amino acids of B50 cells with dose of methamphetamine 
identified by PCA as contributing most to the variance observed between samples. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of 48 
hours. Amino acids were chosen from the GC-MS metabolite data, normalised to total ion 
chromatogram and presented as a percentage of the control value. Peak area is mean ± standard 
error. n=3 
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Figure 3.26: Changes in extracellular amino acids of B50 cells with dose of methamphetamine 
identified by PCA as contributing most to the variance observed between samples. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of 48 
hours. Amino acids were chosen from the GC-MS metabolite data, normalised to total ion 
chromatogram and presented as a percentage of the control value. Peak area is mean ± standard 
error. n=3 
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Figure 3.27: Changes in extracellular metabolites of B50 cells with dose of methamphetamine 
identified by PCA as contributing most to the variance observed between samples. Cells were 
incubated with or without methamphetamine (1 µM, 10 µM, 100 µM, 1 mM) for a period of 48 
hours. Metabolites were chosen from the GC-MS metabolite data, normalised to total ion 
chromatogram and presented as a percentage of the control value. Peak area is mean ± standard 
error. n=3 
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The extracellular metabolites chosen for further review have been placed into three groups for 
analysis according to type and direction of change. The first group (Figure 3.25) containing the 
amino acids L-alanine, glycine, L-proline, L-serine and L-threonine, showed an increase in peak 
area as the dose of methamphetamine increased. The second group (Figure 3.26) is the amino acids 
L-isoleucine, L-leucine, L-methionine and L-valine, which followed a trend of decreasing peak 
area with increasing dose. Lastly, non-amino acid metabolites (Figure 3.27). Arabitol and urea 
levels decreased with increasing methamphetamine concentration. The levels of galactofuranose 
remained steady before a sharp decrease in peak area from 1.20 ± 0.11 at 100 µM to 0.88 ± 0.41 at 
1 mM. Both myo-inositol and octadecenoate followed a general increase in peak area as the 
methamphetamine concentration increased. Similarly, uracil levels also increased with dose; 
however, a drop in peak area was recorded at 100 µM (0.86 ± 0.14) before rising again at 1 mM 
(1.71 ± 0.35). 
3.3 Time course 
To measure the biochemical response of B50 neuroblastoma cells to methamphetamine over time, 
a time course experiment was conducted. This analysis compared incubation periods of various 
lengths: a short incubation of 6 hours, an intermediate 24 hours and an extended 48-hour 
incubation. 
3.3.1 Intracellular metabolites 
The PCA created from the intracellular GC-MS dataset is presented in Figure 3.31. The scores plot 
(A), shows the difference between the groups as best modelled by PC-1 (44%) and PC-2 (20%). 
The scores plot shows distinct differences between the different time groups with the control and 
treatment groups for each time period close together. This shows there was more variance based on 
time than based on treatment. The loadings plot (B) identifies the metabolites which accounted for 
the variation between samples. From this data, the change in peak area over time has been 
graphically represented for the metabolites representing the most variance (Figures 3.32 and 3.33).  
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Figure 3.31: Principal component analysis of GC-MS metabolomics data generated from B50 rat 
neuroblastoma cells following exposure to methamphetamine. Cells were incubated with or 
without 1 mM methamphetamine for 6, 24 or 48 hours. (A) Scores plot, with sample groupings 
identified. (B) Loadings plot, showing metabolites and their influence on the sample groupings in 
(A). Data was deconvoluted, compounds identified and normalised to internal standard prior to 
multivariate analysis. 
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Figure 3.32: Changes over time of intracellular amino acids of B50 cells incubated with 
(treatment) or without (control) methamphetamine (1 mM) for periods of 6, 24 or 48 hours. 
Metabolites were identified from the GC-MS metabolite data by PCA as contributing most to the 
variance observed between samples. Data was normalised to total ion chromatogram. Peak area is 
mean standard ± error. n=3 
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Figure 3.33: Changes over time of intracellular metabolites of B50 cells incubated with 
(treatment) or without (control) methamphetamine (1 mM) for periods of 6, 24 or 48 hours. 
Metabolites were identified from the GC-MS metabolite data by PCA as contributing most to the 
variance observed between samples. Data was normalised to total ion chromatogram. Peak area is 
mean standard ± error. n=3 
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The time course results for intracellular amino acids are displayed in Figure 3.32. The amino acids 
L-alanine, L-glutamate, L-methionine and L-threonine showed a similar trend of an increase in 
peak area with increasing incubation time. Of these, only L-glutamate recorded a decrease in levels 
relative to control at 48 hours with peak areas of 1.13 x 10
8
 ± 4.04 x 107 and 6.78 x 107 ± 3.05 x 107 
respectively. L-valine remained steady throughout the time course with fairly similar control and 
treatment levels. 
The other intracellular metabolites identified for further analysis are shown in Figure 3.33. Both 
fructose and glucose followed a trend of decreasing peak area over time. Also displaying a 
decrease over time was hexdecanoate, whose treatment samples were consistently higher than 
control. Myo-inositol and succinate showed a very similar trend of increasing peak area over time 
(from 1.49 x 10
7
 ± 7.50 x 106 to 2.21 x 107 ± 3.40 x 106 for myo-inositol and from 5.70 x 106 ± 2.03 
x 10
6
 to 7.58 x 10
6
 ± 2.63 x 106 for succinate, from 6 hour to 48 hour treatments respectively) with 
treatment levels beginning high relative to control and finishing below control at 48 hours. Levels 
of treatment samples were generally low compared to control for tryptamine, which displayed an 
increasing trend over time (from 6.60 x 10
6
 ± 3.53 x 106 at 6 hours treatment to 15.81 x 107 ± 6.81 
x 10
6
 at 48 hours treatment). 
 
3.3.2 Extracellular metabolites 
A PCA was also constructed for the extracellular metabolomic data (Figure 3.34). As shown in the 
scores plot (A), this data is described by PC-1 (33%) and PC-2 (27%). There is clear distinction 
between the groups, with the treatment and control group for each time period clustering together. 
The metabolites distinguishing the groups are given in the loadings plot (B). A number of these 
metabolites were examined further through graphical representation of the changes over time 
(Figures 3.35 and 3.36). 
An increase in peak area over time was found for the amino acids L-alanine, L-phenylalanine and 
L-proline. The treatment sample for L-alanine was considerably lower than control level at the 48  
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Figure 3.34: Principal component analysis of GC-MS metabolomics data generated from medium 
obtained from B50 rat neuroblastoma cells following methamphetamine exposure for 6, 24 or 48 
hours. (A) Scores plot, with sample groupings identified. (B) Loadings plot, showing metabolites 
and their influence on the sample groupings in (A). Data was deconvoluted, compounds identified 
and normalised to internal standard prior to multivariate analysis. 
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Figure 3.35: Changes over time of extracellular amino acids of B50 cells incubated with 
(treatment) or without (control) methamphetamine (1 mM) for periods of 6, 24 or 48 hours. Amino 
acids were identified from the GC-MS metabolite data by PCA as contributing most to the variance 
observed between samples. Data was normalised to total ion chromatogram. Peak area is mean 
standard ± error. n=3 
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Figure 3.36: Changes over time of extracellular metabolites of B50 cells incubated with 
(treatment) or without (control) methamphetamine (1 mM) for periods of 6, 24 or 48 hours. 
Metabolites were identified from the GC-MS metabolite data by PCA as contributing most to the 
variance observed between samples. Data was normalised to total ion chromatogram. Peak area is 
mean standard ± error. n=3 
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hour mark (48 hours control, 1.55 x 10
6
 ± 2.62 x 105 and 48 hours treatment, 5.42 x 105 ± 3.08 x 
10
5
). L-phenylalanine treatment samples were above control at all incubation times. A trend of 
decreasing peak area over time was shown by L-isoleucine, L-serine and L-valine. At the 24- and 
48-hour time periods (1.32 x 10
7
 ± 6.82 x 106 and 1.05 x 107 ± 6.35 x 106 respectively), the levels 
of L-serine treatment samples were noticeably higher than control (6.32 x 10
6
 ± 4.52 x 106 and 4.22 
x 10
6
 ± 4.75 x 106 respectively). 
Of the extracellular metabolites presented in Figure 3.36, only myo-inositol followed a trend of 
decreasing peak area over time (7.22 x 10
7
 ± 2.19 x 107 at 6 hours treatment and 5.40 x 107 ± 1.02 
x 10
7
 at 48 hours treatment) with the remaining metabolites increasing over time. The glycerol 
samples show a noticeable increase in peak area from 24 to 48 hours (2.64 x 10
5
 ± 3.61 x 104 at 24 
hours treatment to 7.06 x 10
5 ± 2.52 x 105 at 48 hours treatment). The levels of treatment samples 
compared to control remained fairly similar for all metabolites analysed. 
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4. Discussion 
4.1 Cell viability testing 
To demonstrate the neurotoxic effects of methamphetamine at a range of doses, neuronal cells 
were exposed to the drug and the cells subsequently photographed (Figure 3.11). The clumping and 
aggregation observed upon methamphetamine administration shows that the drug caused visible 
morphological damage to these cells. This damage would affect neuronal function and result in the 
loss of neuronal viability.  
The B50 cells displayed increased aggregation and altered morphology when exposed to high 
concentrations of methamphetamine compared to low concentrations. This shows that the degree 
of damage due to methamphetamine was dose-dependent, with damage increasing with increased 
dose. 
To test whether the visible damage translated into cytotoxicity and cell death, an LDH assay was 
performed. It was expected that cytotoxicity would increase as the dose of methamphetamine 
increased. However, the results of the LDH assay were unusual, with the 10 µM and 100 µM doses 
of methamphetamine resulting in cytotoxicity below control and the 1 µM levels (Figure 3.12). 
These results are in conflict with those of Huang et al. (2009) and Zhou et al. (2004), who found a 
dose-dependent increase in cytotoxicity in response to methamphetamine by quantifying LDH. 
Zhou and colleagues (2004) reported a cytotoxicity level 30.2% above control for 1 mM 
methamphetamine after 48 hours. This is considerably higher than the result of 6.96% above 
control for the same dosage achieved in this experiment. In keeping with the results of this 
experiment, Huang and colleagues (2009) found that methamphetamine concentrations at and 
below 1 mM did not have a significant cytotoxic effect after 24 hours of exposure. However, 
Welder (1992) reported a significant LDH release for 1 mM methamphetamine in the same time 
frame. This disparity may be due to a difference in method or cell type used, as some cell types 
may be more susceptible to the effects of methamphetamine than others. To discount the 
possibility of interference on the LDH results, both the modified DMEM and methamphetamine 
used in the experiment were analysed using the procedure given in 2.23. Neither was found to 
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cause interference effects or react with the reagents. It may be that this LDH test kit is unsuitable 
for the cell culture model used in this experiment. 
Due to the inconsistent results obtained using LDH assay, Trypan blue exclusion testing was 
conducted as a comparison (Figure 3.13). The results of this test showed a decrease in cell viability 
with increased dose of methamphetamine. This result is backed up by similar findings by Wu et al. 
(2007). However, the decrease in viability found in this experiment was greater than that reported 
by Wu. After 48 hours exposure to 1 mM methamphetamine the viability was found to be 69.9% 
compared to control. In contrast, Wu and colleagues (2007) found a viability of 85% compared to 
control for 1 mM. The decrease in viability for the other concentrations tested was also greater than 
that found by Wu et al. (2007) who saw very little change in viability for concentrations below 1 
mM using Trypan blue. Possibly the B50 cell type used in this experiment was more sensitive to 
methamphetamine than that used by Wu. A difference in the method used may also account for 
these changes, as the vortex used in this experiment to separate cells from medium may have 
caused additional damage to cell membranes. Also, as Trypan blue counting techniques rely on 
observing the change in colour of the cells, human error could play a part in the discrepancies. 
4.2 Dose curve 
In order to study the biochemical response of neuronal cells to methamphetamine administration, a 
dose curve was established, comparing the changes within the cell and the surrounding medium at 
a range of doses. Those metabolites that showed the most difference between doses were chosen 
for further analysis, a large proportion of which were amino acids. Other metabolites affected 
included carbohydrates, fatty acids and organic compounds. 
The release of the excitatory amino acid and neurotransmitter glutamate is known to occur as part 
of the neurotoxic action of methamphetamine. This event is highly dependent on the influx of Ca
2+
 
and causes the continued activation of glutamate receptors, leading to excitotoxicity and neuronal 
death (Jayanthi et al., 2005). Further damage is caused by the influx in Ca
2+
 through the activation 
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of kinases, proteases and lipases, the breakdown of cytoskeletal proteins and the production of free 
radicals and resulting DNA damage (Quinton et al., 2006).  
The metabolite N-acetylglutamate is a product of glutamate and therefore is reflective of glutamate 
levels within the cell (Caldovic and Tuchman, 2003). Upon exposure to methamphetamine, the 
amount of N-acetylglutamate within the cell was found to increase relative to control, before 
decreasing at the highest methamphetamine concentration. Release of glutamate is enhanced by 
methamphetamine administration (Pederson et al., 2000) and may be responsible for the increase 
in N-acetylglutamate.  The reduction in N-acetylglutamate at high doses of methamphetamine may 
be due to protective mechanisms lowering the amount of free glutamate available and thereby 
reducing excitotoxicity. 
The amount of L-threonine detected within the treated cell followed a bell shaped curve, with 
levels increasing until 100 µM and then decreasing. The decrease of L-threonine seen with higher 
doses could be due to the amino acid being transported out of the cell to the media. This coincides 
with the increase in extracellular L-threonine at 1 mM methamphetamine. The reduction of 
intracellular L-threonine may also be accounted for by conversion to glycine via serine 
hydroxymethyl transferase followed by export to the medium (Fraser and Newman, 1975). This is 
supported by an increased detection of glycine within the medium. Glycine has neurotransmitter 
properties and acts as a co-agonist with glutamate for the NMDA receptor. Excessive stimulation 
of this receptor can result in excitotoxic damage (Laube et al., 1997).  
The amino acid L-proline is an intracellular metabolite that was found to be affected by 
methamphetamine. Proline is synthesised from its precursor, L-glutamate, via a number of steps 
(Jones, 1985). The decrease in availability of glutamate as a precursor could explain the reduced 
levels of proline at high doses of methamphetamine. Export of proline to the extracellular space 
could provide another possible explanation for the decrease. This is supported by a corresponding 
increase in proline levels in the medium at 1 mM methamphetamine. 
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The level of urea within the medium was found to decrease with increasing methamphetamine 
concentration. In the urea cycle, urea is produced as a by-product during the conversion of arginine 
to ornithine. Ornithine is then able to undergo further changes to produce proline (Brown and 
Cohen, 1959). The increased intracellular proline at low concentrations of methamphetamine could 
cause increased production of urea. As a waste product, urea would then be transported out of the 
cell to the medium. Also, as proline levels decreased, so would urea production, further 
establishing the production of urea as a result of proline synthesis. 
Another neurotoxic event known to occur in response to methamphetamine is the production of 
damaging ROS of which there are a number of potential sources. Firstly, excess dopamine released 
into the cytosol can undergo auto-oxidation to dopamine quinones, which are further converted to 
toxic radicals (Thrash et al., 2009). A second source of ROS is derived from serotonin toxicity 
(Barr et al., 2006) and lastly, the mitochondria are known to produce ROS as a side product of 
ATP synthesis and as a result of electron transport chain dysfunction (Brown et al., 2003). 
To combat the oxidative stress caused by methamphetamine-induced ROS the cell may increase 
the release of antioxidant substances. The level of L-serine within the treated cell was found to 
increase with increasing dose of methamphetamine. This could be a protective response to the 
oxidative damage as serine has been shown to possess anti-oxidant effects. It has been suggested 
that L-serine supports the growth and survival of neurons and is essential for specific brain 
functions (Wang et al., 2010). Within the medium, the levels of L-serine were found to increase at 
1 mM methamphetamine. This may be caused by expulsion from within the cell due to high 
intracellular L-serine causing transport to the medium in an attempt to restore homeostasis. 
Octadecenoate, a salt or ester of the fatty acid oleic or octadecenoic acid, was also affected by 
methamphetamine administration. The increased production of ROS within the cell associated with 
methamphetamine exposure, could lead to the breakdown of fatty acids by per-oxidation (Thrash et 
al., 2009; Catala, 2009). This may account for the initial increase in octadecenoate seen within the 
treated cell. As a fatty acid derivative, octadecenoate may also be utilised as a fuel source causing 
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levels of the metabolite to decrease with increased methamphetamine concentration. Another 
possibility is that octadecenoate was transported out of the cell, reducing intracellular levels. This 
idea is plausible given the increase in octadecenoate within the medium. 
Other intracellular amino acids which decreased as methamphetamine dose increased were L-
isoleucine, L-leucine and L-valine. These amino acids all rely on pyruvate as a precursor for their 
synthesis (Freundlich et al., 1962). Pyruvate is produced as a product of glycolysis, the metabolic 
pathway employed by tissues to produce energy in the form of ATP via the oxidation of glucose 
(Ferrier, 2011). The reduction of these metabolites suggests that less pyruvate was available within 
the cell as methamphetamine damage increased, which may be due to inference with energy 
production. 
Galactose levels greatly increased within the cell as the dose of methamphetamine increased. 
Metabolism of galactose via the Leloir pathway results in the production of UDP-glucose which is 
able to participate in glycolysis (Ferrier, 2011). A build-up of galactose within the cell suggests 
dysfunction of the mechanisms responsible for clearing galactose and dysfunctional energy 
production pathways. 
4.2.1 Overall discussion of dose curve 
Most affected by increased methamphetamine concentration were metabolites related to energy 
production and utilisation. These included octadecenoate, amino acids L-isoleucine, L-leucine and 
L-valine, and galactose. 
Changes in N-acetylglutamate, L-proline and glycine with the dose of methamphetamine were 
observed which may be in response to increased glutamate release and excitotoxicity associated 
with methamphetamine administration.  
The overall picture of methamphetamine toxicity is that glutamate is released in response to 
methamphetamine administration, which causes excitotoxicity and oxidative stress. These cause 
damage to the cell, disrupting energy production. The cell utilises a number of mechanisms to 
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attempt to reduce oxidative stress, but as dose increases, the degree of damage also increases, 
making it difficult for the cell to survive. 
4.3 Time course 
The time dependency of the biochemical response of B50 cells to methamphetamine was analysed 
using a time course experiment. Using a dose of methamphetamine known to be toxic to neuronal 
cells, a number of time points were targeted, 6-, 24- and 48 hours. The metabolites identified as 
showing the most variance between the samples included, amongst others, amino acids, 
carbohydrates and fatty acids. 
Release of glutamate, an amino acid neurotransmitter, was increased at 24 hours as a result of 
methamphetamine administration. The released glutamate would be able to cause excessive 
stimulation of glutamate receptors such as NMDA, leading to excitotoxicity and nitric oxide 
production, which can be highly damaging to the cell (Pederson et al., 2000).  
The levels of intracellular L-glutamate changed greatly over the 48-hour period with the largest 
change occurring between 6 and 24 hours. At 6 hours, the amount of glutamate present in treated 
cells was less than that in control. This reversed at 24 hours, with treated cells having greater 
glutamate than control. A possible reason for this change is the release of glutamate triggered by 
methamphetamine. This excess glutamate could lead to excitotoxic damage through the over-
activation of glutamate receptors (Pederson et al., 2000). N-acetylglutamate was found to increase 
in the medium over time. Release of glutamate, the precursor of N-acetylglutamate, is enhanced by 
methamphetamine exposure (Caldovic and Tuchman, 2003). As excess glutamate can have 
detrimental effects due to the activation of NMDA receptors (Pederson et al., 2000), it would 
benefit the cell to remove glutamate via conversion to N-acetylglutamate and expulsion from the 
cell. 
The increase in intracellular glutamate could account for the changes in L-alanine in 
methamphetamine treated cells. L-alanine levels showed an increase over time, increasing greatly 
when compared to control at 48 hours. This could be due to glutamate being converted to alanine 
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via the enzyme alanine transaminase in an attempt to reduce intracellular glutamate and thereby 
excitotoxicity (Matthews et al., 2000). This effect was noted by Matthews et al. (2000), who 
reported increased neuronal viability after glutamate exposure in the presence of alanine 
transaminase. Uptake of alanine from outside the cell could also contribute to this increase in 
alanine. This is supported by the corresponding decrease in extracellular alanine at 48 hours. 
An extracellular metabolite found to increase over time after methamphetamine treatment was 
myo-inositol. This result is confirmed by Ernst et al. (2000), who detected an increase in myo-
inositol in the frontal grey matter after methamphetamine exposure. Myo-inositol is considered an 
indirect marker of glial cell integrity (Perrine et al., 2010). Inhibition of myo-inositol containing 
IP3 receptors reduces Ca
2+
 release suggesting that it is also involved in regulation of intracellular 
calcium concentration (Gerasimenko et al., 2006). Myo-inositol could be increased in an effort to 
reduce the Ca
2+
 influx brought about by methamphetamine-induced excitotoxicity. The increase in 
intracellular myo-inositol could also be accounted for by an intake from the medium as shown by a 
decrease in extracellular myo-inositol. 
Methamphetamine exposure is associated with an increased production of ROS. This is brought 
about through the auto-oxidation of monoamines such as dopamine, excitotoxicity, and the 
production of ATP and the inhibition of the electron transport chain within the mitochondria 
(Thrash et al., 2009; Barr et al., 2006; Brown et al., 2003). ROS can have damaging effects on 
amino acids, phospholipids and nucleic acids (Cunha-Oliveira et al., 2008). 
The amino acids L-methionine and L-serine were also influenced by methamphetamine 
administration. The levels of methionine were found to increase over time while serine decreased. 
These metabolites are known to have antioxidant properties (Levine et al., 2000; Wang et al., 
2010) and could be produced in response to the production of ROS brought about by 
methamphetamine toxicity (Barr et al., 2006). Serine levels were highest at 6 hours, while 
methionine was greatest at 48 hours. This suggests that there are two ROS events occurring, an 
initial event occurring soon after exposure and a delayed event. 
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Levels of glycerol were also shown to be elevated over time in the medium of methamphetamine-
treated cells. Glycerol forms an important structural component of cell membranes (Nelson and 
Cox, 2013). Methamphetamine is known to cause the release of ROS through monoamine 
autooxidation and mitochondrial damage (Trash et al., 2009; Brown et al., 2003). The 
consequential oxidative stress may cause damage to cellular structures including cell membranes 
(Cuhna-Oliveira et al., 2008) which would result in the release of glycerol and the death of the cell.  
Both glucose and fructose followed a trend of decreasing peak area over time within the cell when 
exposed to methamphetamine. The ROS produced in response to methamphetamine would have an 
adverse effect on mitochondrial function. Damage to the mitochondria could result in a decrease in 
aerobic respiration which could lead to the cell using carbohydrates at an accelerated rate. This 
may explain the decrease in both glucose and fructose over the time course. A metabolomic study 
by McClay and colleagues (2013) also reported a decrease in fructose concentration after 
methamphetamine administration. 
Levels of intracellular succinate, a TCA cycle intermediate, also increased over time. 
Mitochondrial damage from ROS could also have resulted in TCA cycle dysfunction. This could 
lead to a build-up of succinate over time. The finding of increased succinate levels after 
methamphetamine administration is supported by the work of McClay et al, (2013).  
The release of catecholamines such as dopamine and serotonin by methamphetamine is well 
established. Methamphetamine administration results in the accumulation of catecholamines 
through redistribution from storage vesicles to the cytosol, transport to the synapse and prevention 
of reuptake, increasing the risk auto-oxidation of catecholamines to harmful compounds (Thrash et 
al., 2009).  
Levels of L-phenylalanine within the medium were elevated compared to control at all time points 
tested. The catecholamine precursor tyrosine is produced from the hydroxylation of phenylalanine 
(Scarnà et al., 2003). The release and production of catecholamines is triggered by the actions of 
methamphetamine and is known to cause long-term damage to nerve terminals (Friedman et al., 
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1998). Therefore the increased release of phenylalanine into the medium may be an attempt to 
reduce the production of catecholamines.  
4.3.1 Overall discussion of time course 
The majority of metabolites affected by methamphetamine over time were related to the increased 
release of glutamate brought about by methamphetamine treatment. These were the increase in L-
glutamate, N-acetylglutamate and L-alanine, and the decrease in myo-inositol. These changes 
occurred slowly, building to peak at 48 hours. 
Increased levels of L-methionine at 48 hours, L-serine at 6 hours and glycerol, which greatly 
increased between 24- and 48-hours may be in response to the damaging effects of ROS, known to 
be caused by methamphetamine. 
A disruption to energy production by methamphetamine is reflected in the changes to glucose, 
fructose and succinate and an attempt to reduce catecholamines is shown by the reduction of L-
phenylalanine. This effect occurred early in the time course, with changes evident as early as 6 
hours. 
4.4 Effect of methamphetamine 
The exposure of B50 cells to methamphetamine affected several aspects of metabolism, including 
changes to glutamate, carbohydrates, fatty acids and amino acids. 
Changes were observed in cellular glutamate production as shown by increased L-glutamate, N-
acetylglutamate, L-alanine and L-proline. These changes are reflective of the release of glutamate 
and subsequent excitotoxic effects that are known to be associated with methamphetamine 
administration (Pederson et al., 2000). The increase in glutamate is highly dependent on the influx 
of Ca
2+
, the majority of which is taken up by mitochondria, causing further damage (Brown et al., 
2003). The increase in N-acetylglutamate, L-alanine and L-proline, as products of glutamate 
(Caldovic and Tuchman, 2003; Matthews et al., 2000; Jones, 1985), suggests attempts by the cell 
to reduce intracellular glutamate through diversion to other pathways. 
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A number of carbohydrates and fatty acids were also affected; suggesting alterations in energy 
pathways are brought about by methamphetamine treatment. Decreased levels of fructose and 
glucose within the cell may have resulted from the break down of aerobic respiration brought about 
by mitochondrial damage (Brown et al., 2003), causing an accelerated rate of carbohydrate use. 
The increase in octadecenoate, a derivative of oleic acid, suggests that the cell was increasingly 
utilising fatty acid as an energy source. The fatty acid glycerol was also found to increase. This 
may be caused by an increased production of ROS in response to methamphetamine treatment. 
ROS may arise from mitochondrial damage and dopamine and serotonin oxidation causing damage 
to cellular structures such as the glycerol-containing cell membranes (Cuhna-Oliveira et al., 2008). 
The group most widely affected by methamphetamine was the amino acids. Amino acids are 
involved in numerous pathways and have a vast variety of functions, making it difficult to 
determine the reasons for their involvement with confidence. The increase in L-serine and L-
methionine, which are known to have antioxidant properties, could be brought about to combat the 
increased ROS associated with methamphetamine toxicity (Brown et al., 2003). Another protective 
response to methamphetamine was seen in the changes to L-phenylalanine levels. As 
catecholamines are known to rise to damaging levels after methamphetamine administration, a 
decrease in phenylalanine, a precursor for catecholamines, would reduce further formation (Scarnà 
et al., 2003). 
The neurotoxic effects of methamphetamine include monoamine release, oxidative stress, 
excitotoxicity, mitochondrial damage and alterations to energy utilisation. The changes in 
metabolite levels over dose and time of methamphetamine treated cells and medium were 
reflective of these effects. 
4.5 Limitations and expansions 
As a preliminary study, this work has a number of factors which may limit the interpretation of the 
data contained within.  
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The study employed the use of cell cultures to simulate the neurotoxic effects of methamphetamine 
upon the brain. Whilst this method is convenient and eliminates any differences between test 
subjects, as may be found in animal studies, it uses a single cell type to represent the entire CNS. 
To examine the biochemical changes of the CNS as a whole, an in-vivo method could be applied, 
or alternatively, a mixed brain cell culture as used by Fabian and Rea (1993). 
An untargeted metabolomics approach was used in this study to identify metabolites of interest. 
While limited information of specific metabolites affected by methamphetamine made this 
necessary, further studies could benefit from a targeted approach. This would allow a more precise 
quantification and a more in-depth look at the metabolites (Almstetter et al., 2012). The 
metabolomic data obtained from the dose curve and time course experiments showed considerable 
variance between the replicates, evident in the size of the standard error. As this is preliminary 
work, some variation in the results is to be expected until methods are consolidated. The sample 
size used for these experiments was also small, adding to the variance. To improve this aspect, a 
larger number of replicates might be used and all experiments should be performed on the same 
passage of cells at the same time, instead of in separate batches as was done here.  
This study was limited to the administration of methamphetamine at a single time point. 
Continuation of this work may utilise repeated doses of methamphetamine to simulate real-life 
drug use. In addicts, patterns of methamphetamine administration often show repeated, high dose 
binging, taken within a short period of time (Segal and Kuczenski, 1997). This could be easily 
emulated, in vitro, as a comparison to a single toxic dose. 
 
4.6 Conclusion 
 
This work has shown that methamphetamine causes visible and dose-dependent damage to 
neuronal cells. The viability of cells treated with methamphetamine at a range of doses was able to 
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be quantified via Trypan blue exclusion testing which demonstrated that cell death occurred in 
response to methamphetamine administration. 
These experiments found that methamphetamine exposure resulted in measurable biochemical 
changes over dose and time. The use of a metabolomic method provided a snap shot of the activity 
of the cell giving new information on the biochemical response of the cell. These metabolite 
changes were reflective of the known mechanisms of methamphetamine toxicity including 
glutamate release and excitotoxicity, changes to energy utilisation and production of ROS. The 
result of this study furthers our understanding of neurochemical processes in response to 
methamphetamine and could potentially lead to the identification of therapeutic targets. 
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